Effect of Danshen-containing serum on expression of SuFu and DYRK2 in HSCs.
- Author:
Shi-qing HAN
;
Hai-lan WANG
;
Li-li FENG
;
Wen-fu CAO
- Publication Type:Journal Article
- MeSH:
Animals;
Drugs, Chinese Herbal;
administration & dosage;
Female;
Hepatic Stellate Cells;
drug effects;
metabolism;
Humans;
Liver Cirrhosis;
drug therapy;
genetics;
metabolism;
Male;
Protein-Serine-Threonine Kinases;
genetics;
metabolism;
Protein-Tyrosine Kinases;
genetics;
metabolism;
Rats;
Rats, Sprague-Dawley;
Repressor Proteins;
genetics;
metabolism;
Salvia miltiorrhiza;
chemistry
- From:
China Journal of Chinese Materia Medica
2015;40(22):4469-4474
- CountryChina
- Language:Chinese
-
Abstract:
To observe the effects of Danshen-containing serum on SuFu and DYRK2 expression in the HSCs stimulated by leptin. SD rats (n = 60) were used to make danshen-containing serum by gastric perfusion for ten days with Danshen water decoction, normal saline and colchicine. The HSCs that were cultured in vitro would be stimulated for 24 hours by leptin (100 μg x L(-1)) except blank control group, after being intervened, the drug serum in each group would be cultured at 37 degrees C in 5% incubator. The cells would be collected after 24 hours, then the effects of danshen-containing serum on the proliferation of HSCs were detected by MTT, the expression of SuFu mRNA and DYRK2 mRNA were detected by RT-PCR, the expression of SuFu and DYRK2 proteins were tested by Western blot. Compared with blank control group, the expression of DYRK2 mRNA and DYRK2 proteins were enhanced obviously after stimulated the HSCs of rats by leptin (P < 0.01), but the expression of SuFu mRNA and SuFu proteins were decreased significantly (P < 0.01). Compared with the model group, after cyclopamine group (Hh pathway inhibitor), Danshen-containing serum and colchicine were interfered, the expression of DYRK2 mRNA and DYRK2 proteins were decreased clearly (P < 0.01), but the expression of SuFu mRNA and SuFu proteins were increased significantly (P < 0.01 or P < 0.05). Compared with model group, adding purmorphamine (Hh pathway agonist) to model group and making it activate could increase the expression of DYRK2 mRNA and DYRK2 proteins, but the expression of SuFu mRNA and SuFu proteins were decreased significantly (P < 0.01). Compared with the model group, using the Danshen-containing serum to interfere the purmorphamine group could make the expression of DYRK2 mRNA and DYRK2 proteins decrease and the expression of SuFu mRNA and SuFu proteins increase significantly (P < 0.01). Danshen-containing serum would inhibition the activation and increment of HSCs by interfering the expression of SuFu and DYRK2 which were induced by leptin.
